NZ Lymphoma / Leukaemia Research Review Issue 52

In this issue:

Leukaemia selection

Risk-adapted BR: tolerable in elderly patients with CLL
Dasatinib + blinatumomab for Ph+ ALL
3-year relapse risk in ALL
Azacitidine maintenance vs. observation after transplant in high-risk AML/MDS
Anti-CD19 CAR T-cell therapy in ALL

Lymphoma selection
Brentuximab vedotin + bendamustine as bridge to autologous SCT in refractory/relapsed classical  Hodgkin’s lymphoma
Predicting and preventing CNS relapse in extranodal NK/T-cell lymphoma
CAR T cells vs. alternative therapies for DLBCL
Consolidation RT in advanced Hodgkin’s lymphoma with large nodal mass
Venetoclax + rituximab ±bendamustine vs. BR in relapsed/refractory follicular lymphoma

Please login below to download this issue (PDF)